Fate Therapeutics Inc (FATE) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Fate Therapeutics Inc   (NASDAQ: FATE)
 

Fate Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FATE Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 9.18 % 5.15 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 60.28 % -11.92 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) -23.36 % 5.66 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 2.77 % 1.16 % 2.03 % 2.61 %
Revenue 5 Year Average Growth -26.71 % 8.2 % 8.65 % 10.59 %


FATE's Growth Comparisons in II. Quarter 2026




Facing 9.18% year on year sales decrease in the second quarter 2026, to $ 2 millions, Fate Therapeutics Inc reported smaller declines than the Biotechnology & Pharmaceuticals industry with 5.15%, and less than 8.91% growth in the Healthcare sector. Slow second quarter sales in the Biotechnology & Pharmaceuticals industry and Healthcare sector, were portrayed in Fate Therapeutics Inc 's results, which underperformed overall market.

Top-line grew by 60.28% from the first quarter. Average yearly sales growth for Fate Therapeutics Inc is -26.71%, while S & P 500's average annual sales increase is 10.59% over the five years, including only Businesses with the second quarter 2026 Results.

FATE Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Member
-
-
Total
9.18 %
60.28 %


Growth Rates of FATE's Income in the second quarter 2026


FATE Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - 434.95 % 4.62 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) - -48.89 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) - 954.66 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) - 230.06 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - -18.41 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -78.96 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) - - -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) - -86.66 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) - -59.21 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -11.5 % 0.17 % -28.52 %

FATE Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -78.9 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) - -86.69 % -0.77 % 27.07 %
Y / Y Net Income Change (Q2 TTM) - 103.06 % 15.51 % 57.33 %
Sequential Net Income Change (Q2 TTM) - -7.95 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth - -8.55 % 9.21 % 22.96 %

FATE's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -82.2 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) - - -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) - - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - 49.32 % 0.17 % -28.52 %



FATE EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -82.15 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) - -88.25 % -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) - - - 4.93 %
EPS Net 5 Year Avg. Change - -8.55 % 9.21 % 22.96 %



Fate Therapeutics Inc reported bottom-line of $ -0.25 in the second quarter, compare to $ -0.29 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry fell by -82.15%, while Healthcare sector decreased by -26.26%, and overall market improved by 90.69%.

The bottom-line grew by 60.28% from the first quarter. Average yearly income per share growth for Fate Therapeutics Inc is -26.71%, while S & P 500's average annual income per share increase is 22.96% over the five years, including only Businesses with the second quarter 2026 earnings reports.

FATE Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) - 6160.46 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) - -53.57 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) - 14 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) - 16.85 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - -14.51 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - 36.63 % - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) - 784.84 % - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change -33.7 % 23.25 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) -94.13 % 32.26 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) -66.53 % -1.95 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) 17.87 % -4.97 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) -25.66 % 8.05 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change 3.83 % 9.64 % 9.12 % 14.73 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.